Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

15.4K
Here, we present a protocol for the production and pre-clinical testing of murine CD19 CAR T cells by retroviral transduction and utilization as a therapy against established syngeneic A20 B-cell lymphoma in BALB/c mice with or without lymphodepleting...
15.4K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

797
Given the limited xenograft models available to study interactions between human CART and myeloid cells, we established in vitro and in vivo models to understand the impacts of human macrophages on CART cells. Findings can potentially be generalized to evaluate macrophage roles in the tumor microenvironment and test macrophage-targeted...
797
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

11.6K
Mantle cell lymphoma (MCL) is a difficult to treat B cell disorder and it is equally difficult to establish a xenograft mouse model of primary MCL to study and develop therapeutics. Here, we describe the successful establishment of MCL xenografts in mice to help understand its underlying...
11.6K
A Spheroid Killing Assay by CAR T Cells08:19

A Spheroid Killing Assay by CAR T Cells

17.1K
This protocol is designed to assess immunotherapeutic redirected T-cell (CAR T-cell) cytotoxicity against 3D structured cancerous cells (spheroids) in real...
17.1K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

766
This protocol provides a detailed description of the generation, culture, and analysis of mantle cell lymphoma in 3D printed hydrogel tumor...
766
An In Vitro Assay to Evaluate the Anti-Tumor Activity of Tumor-Specific CAR T Cells02:42

An In Vitro Assay to Evaluate the Anti-Tumor Activity of Tumor-Specific CAR T Cells

568
This video demonstrates an in vitro assay to validate chimeric antigen receptor (CAR) T cell activity. B-cell lymphoma cells expressing CD19 antigen and cytoplasmic luciferase are co-cultured with CD19-specific CAR T cells. CAR binding to CD19 on a tumor induces the CAR T cells to release cytokines and toxins that cause tumor cell cytotoxicity. The CAR T cell activity is evaluated by quantifying the released cytokine and decreased luciferase-mediated bioluminescence in the tumor...
568

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biological properties and potential pathogenic mechanisms of oral bacterial-derived extracellular vesicles in oral and systemic diseases.

Extracellular vesicles and circulating nucleic acids·2026
Same author

Axitinib promotes stemness and vasculogenic mimicry in triple-negative breast cancer by disrupting THBS1-CD47 axis-mediated endothelial-tumor cell communication.

Apoptosis : an international journal on programmed cell death·2026
Same author

Integration of bulk RNA-seq and scRNA-seq reveals cell subsets and gene signatures associated with Glaesserella parasuis infection.

BMC genomics·2026
Same author

Allogeneic HSCT For Pediatric Extranodal NK/T-Cell Lymphoma Transformed From Chronic Active Epstein-Barr Virus Infection: A Case Report.

Journal of visualized experiments : JoVE·2026
Same author

Macrophage spatiotemporal plasticity in pulmonary diseases: decoding the niche at single-cell resolution.

Frontiers in immunology·2026
Same author

Intelligent regulation of NH<sub>2</sub>-UiO-66 decorated surface molecularly imprinted polymers: targeted recognition and precise control of three typical anthraquinone compounds.

Talanta·2026

Related Experiment Video

Updated: Jan 20, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.4K

Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large

Shuhong Li1, Liqiong Liu2, Zelin Liu2

  • 1State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China.

Antibody Therapeutics
|January 19, 2026
PubMed
Summary

New CD19/CD22 chimeric antigen receptor (CAR-T) cell therapy shows promise for B-cell lymphoma, achieving complete remission in 80% of patients initially. This dual-target CAR-T approach offers a potential new strategy against lymphoma.

Keywords:
CD19CD22DLBCLantigen escapebispecific CAR-T cells

More Related Videos

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

797
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.6K

Related Experiment Videos

Last Updated: Jan 20, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.4K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

797
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.6K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • CD19 and CD22 CAR-T therapies show promise for B-cell lymphoma but face challenges with antigen escape and limited CD22 targeting.
  • Over 50% of patients experience disease progression due to antigen escape, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To engineer and evaluate CD19/CD22 BS Loop CAR-T cells with enhanced CD22 targeting for safety and efficacy.
  • To assess the potential of this dual-target CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma.

Main Methods:

  • Engineered CD19/CD22 BS Loop CAR-T cells with improved CD22 targeting efficacy.
  • Assessed safety and effectiveness in five patients with relapsed/refractory diffuse large B-cell lymphoma.

Main Results:

  • Four out of five patients (80%) achieved complete remission (CR) one month post-infusion; one patient had stable disease.
  • CD19/CD22 BS Loop CAR-T cells showed effective in vivo expansion and were detectable in peripheral blood.
  • All patients experienced only Grade 0-1 cytokine release syndrome, with no observed neurotoxicity.

Conclusions:

  • CD19/CD22 BS Loop CAR-T-cell therapy demonstrated potent antilymphoma activity and addressed dual-antigen targeting challenges.
  • This therapy may offer a safe and effective immunotherapeutic strategy for lymphoma patients.
  • Long-term follow-up showed sustained CR in two patients, while three experienced progression.